Zhang, Y., Babel, R., Fan, T., Amonkar, M., Eiras, R., Vandormael, K. (2026). Impact on overall survival after adjusting for treatment crossover in first-line metastatic NSCLC trials for pembrolizumab plus chemotherapy.. Journal of Clinical Oncology. https://doi.org/10.1200/jco.2026.44.16_suppl.8596